ASX Announcement

Phase 2 CERE-CALM trial expands into Victoria

- **Ethics approval secured for Goulburn Valley Hospital in Victoria, expanding the Phase 2 CERE-CALM clinical trial beyond New South Wales for the first time**
- **Expanded clinical trial network to support patient recruitment, with further Australian sites being considered for inclusion in the study**
- **Clinical site preparations well progressed, with training complete at John Hunter Medical Research Institute and commencing at St Vincent's Hospital Sydney shortly**
- **First patient treatment expected in the coming weeks, following successful enrolment of the first patient in October 2026**

Brisbane, Australia, 19 November 2026 – Ceretas Limited (ASX:CTS) ("Ceretas" or "the Company"), an Australian medical technology company developing a portable, non-invasive therapeutic ultrasound platform to treat Alzheimer's disease and other neurodegenerative conditions, is pleased to advise that St Vincent's Hospital Sydney Human Research Ethics Committee has approved the inclusion of Goulburn Valley Hospital in Victoria as an additional clinical site for its Phase 2 CERE-CALM clinical trial.

The approval expands Ceretas' CERE-CALM trial beyond New South Wales, broadening the Company's Australian clinical trial network and unlocking access to additional patients to support recruitment.

The approval enables Goulburn Valley Hospital to progress through the necessary governance and site start-up activities ahead of local patient recruitment. Ceretas is also advancing opportunities with additional trial sites across the country for inclusion in the study.

The expansion follows earlier ethics approvals for Cognivus Research, St Vincent's Hospital Sydney and John Hunter Medical Research Institute in New South Wales, which provide the Company with an established clinical trial network to support study enrolment and the continued progression of CERE-CALM.

Patient recruitment commenced at Cognivus Research in October, with the first patient successfully enrolled (refer ASX announcement: 29 October 2026). Preparations are also advancing well at other trial sites. Training is now complete at John Hunter Medical Research Institute and is scheduled to commence at St Vincent's Hospital Sydney in December 2026. The Company expects its first patients to receive their first treatment in the coming weeks.

CERE-CALM is a fully funded, randomised, double-blind, sham-controlled Phase 2 trial evaluating low-intensity focused ultrasound neuromodulation as a potential treatment for behavioural and psychological symptoms of dementia (BPSD) in patients with Alzheimer's

disease. The study targets 66 patients (minimum 60), with completion anticipated in H1 CY28.

Management commentary:

CEO and Managing Director, Dr Rachel de las Heras said: *"Expanding CERE-CALM into Victoria is a positive step in building our Australian clinical trial network and strengthening our capacity to recruit patients.*

"With our first patient enrolled and training progressing well at additional sites, we are focused on commencing treatment and expanding recruitment as the trial advances.

"We look forward to bringing further clinical sites into the study as we work towards delivering the next stage of clinical evidence for our therapeutic ultrasound technology."

CERE-CALM Trial Overview

CERE-CALM is a Phase 2 randomised, double-blind, sham-controlled trial evaluating low-intensity focused ultrasound neuromodulation for the treatment of BPSD in adults aged 50 and over with probable Alzheimer's disease.

Participants receive six treatments over 12 weeks, comprising four weekly sessions followed by two monthly sessions.

The primary endpoint is the change in overall neuropsychiatric symptom burden as measured by Neuropsychiatric Inventory (NPI) total score from baseline to week six, comparing active treatment with sham control. Secondary endpoints include caregiver distress, durability of treatment effect and overall safety and tolerability.

The trial targets 66 participants (minimum 60), randomised 2:1 to active treatment or sham control.

The details of the CERE-CALM trial are provided on the Australian and New Zealand public clinical trial registry: www.anzctr.org.au, with trial code ACTRN12626000738325.

This announcement is authorised for release by the Board of Directors.

- ENDS -

For further information please contact

Dr Rachel de las Heras
Chief Executive Officer & Managing Director
racheldelasheras@ceretas.com.au
+61 (0)437 338 079

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 (0)431 271 538

About Ceretas

Ceretas (ASX:CTS) is a clinical-stage medical technology company developing a portable, non-invasive therapeutic ultrasound platform to treat Alzheimer's disease and other neurodegenerative conditions.

The Ceretas device directs low-intensity focused ultrasound through the skull to act on brain tissue via two mechanisms: neuromodulation, targeting neural circuits involved in memory, cognition and the behavioural and psychological symptoms of dementia; and blood-brain barrier opening, which may facilitate clearance of disease-associated proteins and enhance delivery of therapeutic agents to the brain.

The technology is based on more than a decade of research at The University of Queensland and the Queensland Brain Institute (QBI). In 2024, QBI researchers completed a first-in-human Phase 1 trial of low-intensity focused ultrasound neuromodulation in 12 Alzheimer's participants, finding the treatment to be fast, safe and well tolerated, with encouraging early signals of benefit for behavioural symptoms. The results were published in Brain Communications in December 2025.

Ceretas has commenced its Phase 2 CERE-CALM trial (ACTRN12626000738325), evaluating the platform in Alzheimer's patients with behavioural and psychological symptoms of dementia. QBI researchers are separately running their Phase 2 AGIFUS trial (ACTRN12626000687392), evaluating the same technology in Alzheimer's-related agitation, funded independently by Queensland Health.